RNA interference has been developed as a powerful technology for cancer
therapy by intracellular delivery of siRNA and stably silences the specific related genes.
Despite rapid advances regarding the intracellular delivery technologies of siRNA,
cytotoxicity, survivability, and responses still generate significant challenges for the
translation of basic medicine to clinical practices. In this review, biogenesis and function of
siRNAs, current physical approaches for the delivery of siRNA with relative high
survivability and low in cytotoxicity, and immunogenetic responses are discussed. Clinical
evaluations of siRNA for cancer treatment are summarized and analyzed to point out the
significant factors for applying bench technology to nanomedicine. Finally, some of the
potential challenges that may limit the progress of siRNA therapeutics will be highlighted.
Keywords: siRNA, delivery, cancer therapy, cytotoxicity, survivability, clinical evaluation.
Rights & PermissionsPrintExport